secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2026-09-16T21:11:55+00:00
Accession:  0001493152-26-042951
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DataMeds acquires Helomics for $1.5M in stock and convertible note, expanding into cancer diagnostics
--------------------------------------------------------------------------------

- Paid 636,328 shares (~19.99% of MEDS outstanding) plus $1.363M 7% convertible note due Sept 2029; conversion at $1.00/share pending Nasdaq approval.
- Helomics brings CLIA/CAP-certified lab, Predictive Oncology CRO, and $1.5M cash; no third-party debt or unpaid payables.
- Expands DataMEDS beyond GLP-1 and Long COVID into $40B U.S. cancer diagnostic/treatment market.
- Seller Axe Compute (AGPU) retains shareholder stake; agrees to 12-month transfer lock-up and 6-month vote-alignment with DataMeds board.
- Deal closed Sept 11, 2026; Helomics becomes wholly owned subsidiary of DataMeds AI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000149315226042951/0001493152-26-042951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000149315226042951/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer